The uncertainty over the biotech's lead clinical asset weighed on its shares last month.
Compare ADVM Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
Adverum Biotechnologies, Inc.
News & Analysis: Adverum Biotechnologies, Inc.
Investors are running for the hills following the company's latest clinical update.
AbbVie, Adverum Biotechnologies, and Heron Therapeutics could all be gearing up for a strong May. Here's why.
The company's experimental gene therapy for a common cause of blindness showed promise in a clinical trial.
Adverum's lead gene therapy candidate continues to impress in its early-stage trial.
Interim results from an early-stage study of its wet age-related macular degeneration treatment look promising.
Here's how they could keep on rocketing higher.
Here's what to look out for at the American Academy of Ophthalmology's annual meeting later this week.
Even on an up day for the stock market, these companies lost a lot of ground.
The biotech’s gene therapy isn’t helping patients see better.